Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02232646

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Sumitomo Pharma America, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an open label, multi-center, Phase II study of BBI503 administered to adult patients with selected advanced urologic malignancies. The primary objective of this study is to evaluate the disease control rate of patients with renal cell cancer and urothelial carcinoma treated with BBI503.

Conditions

Interventions

TypeNameDescription
DRUGBBI503BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.

Timeline

Start date
2017-01-01
Primary completion
2018-08-01
Completion
2018-08-01
First posted
2014-09-05
Last updated
2023-11-14

Source: ClinicalTrials.gov record NCT02232646. Inclusion in this directory is not an endorsement.